The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

SureCN194686     (2S)-1-[(2S)-3-(3H-imidazol- 4-yl)-2-[[(2S)...

Synonyms: SureCN1371014, RX-77368, CTK2E0606, AR-1J3401, AC1L32TC, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of RX 77368

  • Fos-immunoreactive cells were rare in controls (~1 cell/ganglion), whereas intracisternal RX-77368 (50 ng) increased the number to 24.8 +/- 1.8 and 26.8 +/- 2.2 cells/ganglion in the corpus and antrum, respectively [1].
  • Measurements of core temperature and respiration rate in rats following intra-accumbens or septal injection of TRH, CG 3509 and RX 77368 showed these peptides to reverse pentobarbitone-induced hypothermia and stimulate respiration rate [2].
  • In urethane-anesthetized, gastric fistula rats, intracisternal RX 77368 or TRH induced stimulation of gastric acid output which was rapid in onset, long lasting, and dose-dependent, in doses ranging from 3 to 100 ng/rat for RX 77368, and 0.1 to 1 micrograms/rat for TRH [3].
  • These findings indicate that [4Cl-D-Phe6,Leu17]VIP is an antagonist for exogenous VIP-induced gastric hyperemia and hypotension and that VIP modulates the systemic blood pressure response to IC RX 77368 at 30 ng while not playing a primary role in the increase of GMBF [4].
  • Of particular interest was the finding that RX-77368 not only blocked the effects of NT but also produced hyperalgesia [5].

Psychiatry related information on RX 77368


High impact information on RX 77368


Chemical compound and disease context of RX 77368


Biological context of RX 77368

  • 3. RX-77368 (1.5, 3, 10, 30 and 100 ng, i.c.) dose-dependently increased corpus contractions, expressed as total area under the curve (AUC, mV min(-1)) to 2.6+/-2.5, 6.1+/-5.9, 9.8+/-2.6, 69.7+/-21.7 and 74.9+/-28.7 respectively vs 0.2+/-0.1 after i.c. saline [12].
  • The VIP antagonist did not significantly reduce the GMBF response to IC RX 77368 while enhancing the rise in blood pressure [4].
  • L-NG-Nitro-arginine methyl ester (L-NAME, 3 mg/kg i.v.), an inhibitor of NO synthase, abolished the cytoprotection provided by i.c. RX 77368 [13].
  • The stable analog, RX 77368, unlike TRH, stimulated gastric emptying when the meal was given 60 min after peptide injection [14].
  • These results demonstrate that chemical stimulation of the raphe pallidus and obscurus by RX 77368 stimulates gastric contractility through vagal and muscarinic pathways [15].

Anatomical context of RX 77368


Associations of RX 77368 with other chemical compounds

  • Hepatic DNA synthesis was assessed by [Methyl-3H]thymidine incorporation 6, 12, 24, 48, and 72 hours after intracisternal injection of the TRH analog, RX 77368 (1, 5, 10, and 100 ng), and by 5-bromo-2'-deoxyuridine (BrdU) labeling of the liver section [20].
  • Intracisternal injection (ic) of the stable TRH analog RX 77368 (10 ng) induced significantly higher insulin response in both genders of overnight-fasted GK rats compared with Wistar rats and slightly increased blood glucose in female Wistar rats but significantly decreased it from 193 to 145 mg/100 ml in female GK rats [21].
  • Activation of gastric myenteric cells by intracisternal injection of the stable thyrotropin-releasing hormone (TRH) analog RX-77368, at a dose inducing near maximal vagal cholinergic stimulation of gastric functions, was investigated in conscious rats [1].
  • These data show that i.c. CRF injection acts centrally to inhibit gastric contractions stimulated centrally (i.e. by i.c. RX 77368) but not peripherally (i.e. by carbachol), and by inference reduces the risk of erosion formation induced by some stressors [22].
  • Dose-response studies revealed that the gastric acid secretion induced by submaximal but not high doses of RX 77368 was elevated significantly by p-CPA pretreatment. p-CPA also enhanced the gastric acid output produced by submaximal, but not high doses of the vagal stimulant baclofen, [beta-(p-chlorophenyl)-gamma-aminobutyric acid] [23].

Gene context of RX 77368

  • Contractility was stimulated by intravenous carbachol (100 mg/kg/h) or i.c. injection of the TRH analog, RX 77368 [22].
  • Intravenous CRF was 1/10th as potent in suppressing contractions produced by i.c. RX 77368 [22].
  • Ucn (1, 3 or 10 microg) inhibited RX-77368 (30 ng)-induced increase in total AUC by 28, 62 and 93% respectively vs i.c. saline+RX-77368 [12].
  • Intracisternal injection of TRH or its potent analog RX 77368 appears also as a new, simple method to produce centrally mediated experimental gastric erosions in 24 hr-fasted rats [24].
  • Ucn II (3, 10, and 30 microg/kg, i.v.) did not alter the 20 min net rise in MAP induced by RX-77368 (35.7+/-7.1, 32.6+/-3.3 and 24.6+/-6.9 mm Hg, respectively) compared with vehicle (33.6+/-4.3 mm Hg) [25].

Analytical, diagnostic and therapeutic context of RX 77368


  1. Intracisternal TRH analog induces Fos expression in gastric myenteric neurons and glia in conscious rats. Miampamba, M., Yang, H., Sharkey, K.A., Taché, Y. Am. J. Physiol. Gastrointest. Liver Physiol. (2001) [Pubmed]
  2. Analeptic effects of centrally injected TRH and analogues of TRH in the pentobarbitone-anaesthetized rat. Sharp, T., Tulloch, I.F., Bennett, G.W., Marsden, C.A., Metcalf, G., Dettmar, P.W. Neuropharmacology (1984) [Pubmed]
  3. Potent central nervous system action of p-Glu-His-(3,3'-dimethyl)-Pro NH2, a stabilized analog of TRH, to stimulate gastric secretion in rats. Taché, Y., Goto, Y., Lauffenburger, M., Lesiege, D. Regul. Pept. (1984) [Pubmed]
  4. Influence of [4Cl-D-Phe6,Leu17]VIP on VIP- and central TRH-induced gastric hyperemia. Király, A., Sütó, G., Guth, P., Taché, Y. Peptides (1997) [Pubmed]
  5. Neurotensin-induced antinociception and hypothermia in mice: antagonism by TRH and structural analogs of TRH. Hernandez, D.E., Nemeroff, C.B., Valderrama, M.H., Prange, A.J. Regul. Pept. (1984) [Pubmed]
  6. Central vagal activation increases mucus gel thickness and surface cell intracellular pH in rat stomach. Tanaka, S., Taché, Y., Kaneko, H., Guth, P.H., Kaunitz, J.D. Gastroenterology (1997) [Pubmed]
  7. Central thyrotropin-releasing factor analog prevents ethanol-induced gastric damage through prostaglandins in rats. Yoneda, M., Taché, Y. Gastroenterology (1992) [Pubmed]
  8. Central action of recombinant interleukin-1 to inhibit acid secretion in rats. Saperas, E.S., Yang, H., Rivier, C., Taché, Y. Gastroenterology (1990) [Pubmed]
  9. Medullary sites of action of the TRH analogue, RX 77368, for stimulation of gastric acid secretion in the rat. Ishikawa, T., Yang, H., Taché, Y. Gastroenterology (1988) [Pubmed]
  10. Role of acetylcholine, histamine and gastrin in the acid response to intracisternal injection of TRH analog, RX 77368, in the rat. Yanagisawa, K., Yang, H., Walsh, J.H., Taché, Y. Regul. Pept. (1990) [Pubmed]
  11. Intracisternal injection of a TRH analogue stimulates gastric luminal serotonin release in rats. Stephens, R.L., Tache, Y. Am. J. Physiol. (1989) [Pubmed]
  12. Intracisternal urocortin inhibits vagally stimulated gastric motility in rats: role of CRF(2). Chen, C.Y., Million, M., Adelson, D.W., Martínez, V., Rivier, J., Taché, Y. Br. J. Pharmacol. (2002) [Pubmed]
  13. Role of nitric oxide in the gastric cytoprotection induced by central vagal stimulation. Király, A., Sütö, G., Taché, Y. Eur. J. Pharmacol. (1993) [Pubmed]
  14. Central nervous system action of TRH to stimulate gastric emptying in rats. Maeda-Hagiwara, M., Taché, Y. Regul. Pept. (1987) [Pubmed]
  15. Thyrotropin-releasing hormone analog injected into the raphe pallidus and obscurus increases gastric contractility in rats. Garrick, T., Yang, H., Trauner, M., Livingston, E., Taché, Y. Eur. J. Pharmacol. (1992) [Pubmed]
  16. Ventral horn neuropeptides modulate the release of noradrenaline from tissue slices of rat brainstem and ventral thoracic spinal cord. Fone, K.C., Johnson, J.V., Putland, A.P., Bennett, G.W. J. Neurochem. (1991) [Pubmed]
  17. Benzodiazepine interactions with central thyroid-releasing hormone binding sites: characterization and physiological significance. Rinehart, R.K., Barbaz, B., Iyengar, S., Ambrose, F., Steel, D.J., Neale, R.F., Petrack, B., Bittiger, H., Wood, P.L., Williams, M. J. Pharmacol. Exp. Ther. (1986) [Pubmed]
  18. Central autonomic activation by intracisternal TRH analogue excites gastric splanchnic afferent neurons. Adelson, D.W., Wei, J.Y., Yashar, M., O-Lee, T.J., Taché, Y. J. Neurophysiol. (1999) [Pubmed]
  19. Evaluation of early gastric mucosal permeability induced by central thyrotropin-releasing hormone administration. Joh, T., Oshima, T., Takahashi, N., Kaneko, H., Sasaki, M., Kataoka, H., Watanabe, K., Sobue, M., Suzuki, H., Nomura, T., Ohara, H., Itoh, M. Am. J. Physiol. Gastrointest. Liver Physiol. (2005) [Pubmed]
  20. Central thyrotropin-releasing hormone stimulates hepatic DNA synthesis in rats. Yoneda, M., Tamori, K., Sato, Y., Yokohama, S., Nakamura, K., Kono, T., Makino, I. Hepatology (1997) [Pubmed]
  21. Altered glucose and insulin responses to brain medullary thyrotropin-releasing hormone (TRH)-induced autonomic activation in type 2 diabetic Goto-Kakizaki rats. Ao, Y., Toy, N., Song, M.K., Go, V.L., Yang, H. Endocrinology (2005) [Pubmed]
  22. Corticotropin-releasing factor acts on the brain to reduce gastric contractility. Garrick, T., Veiseh, A., Taché, Y., Weiner, H. Psychotherapy and psychosomatics. (1987) [Pubmed]
  23. Serotonin depletion potentiates gastric secretory and motor responses to vagal but not peripheral gastric stimulants. Stephens, R.L., Garrick, T., Weiner, H., Taché, Y. J. Pharmacol. Exp. Ther. (1989) [Pubmed]
  24. Gastric erosions induced by intracisternal thyrotropin-releasing hormone (TRH) in rats. Goto, Y., Tache, Y. Peptides (1985) [Pubmed]
  25. Intravenous urocortin II decreases blood pressure through CRF(2) receptor in rats. Chen, C.Y., Doong, M.L., Rivier, J.E., Taché, Y. Regul. Pept. (2003) [Pubmed]
  26. Thyrotropin-releasing hormone in the dorsal vagal complex stimulates hepatic blood flow in rats. Yoneda, M., Hashimoto, T., Nakamura, K., Tamori, K., Yokohama, S., Kono, T., Watanobe, H., Terano, A. Hepatology (2003) [Pubmed]
WikiGenes - Universities